NL2005194C2 - Pharmaceutical composition for use in the prevention and treatment of gingivitis and parodontitis. - Google Patents

Pharmaceutical composition for use in the prevention and treatment of gingivitis and parodontitis. Download PDF

Info

Publication number
NL2005194C2
NL2005194C2 NL2005194A NL2005194A NL2005194C2 NL 2005194 C2 NL2005194 C2 NL 2005194C2 NL 2005194 A NL2005194 A NL 2005194A NL 2005194 A NL2005194 A NL 2005194A NL 2005194 C2 NL2005194 C2 NL 2005194C2
Authority
NL
Netherlands
Prior art keywords
pharmaceutical composition
composition according
weight
gingivitis
parodontitis
Prior art date
Application number
NL2005194A
Other languages
English (en)
Inventor
Eric Jan Ostwald
Sebastiaan Bokhorst
Original Assignee
Eric Jan Ostwald
Sebastiaan Bokhorst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eric Jan Ostwald, Sebastiaan Bokhorst filed Critical Eric Jan Ostwald
Priority to NL2005194A priority Critical patent/NL2005194C2/en
Priority to BE2011/0484A priority patent/BE1020183A3/nl
Application granted granted Critical
Publication of NL2005194C2 publication Critical patent/NL2005194C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (18)

1. Farmaceutische samenstelling omvattende: - 2 to 25 gew% tocoferolen en/of tocotrienolen; 5 - 15 to 40 gew% ascorbinezuur; - 5 to 30 gew% polyfenolen; en -15 to 30 gew% farmaceutisch acceptabele excipienten en/of verdunmiddelen.
2. Farmaceutische samenstelling volgens conclusie 1, verder omvattende 0,01 and 0,5 10 gew% cho lecalciferol.
3. Farmaceutische samenstelling volgens conclusie 1, verder omvattende 5 tot 10 gew% curcuma longa extract.
4. Farmaceutische samenstelling volgens een van de conclusies 1-3 verder omvattende 15-45 gew% S-adenosylmethionine, bij voorkeur 20-30 gew% S-adenosylmethionine.
5. Farmaceutische samenstelling volgens conclusie 3 of 4, verder omvattende 0,1 tot 3 gew% zink of zouten daarvan en/of sporen van selenium. 20
6. Farmaceutische samenstelling volgens een van de conclusies 1-5, waarin de polyfenolen zijn verkregen uit een groene thee extract.
7. Farmaceutische samenstelling volgens een van de conclusies 1-6, waarin de 25 tocoferolen zijn alfa-, beta, gamma of delta tocoferol, of een mengsel daarvan.
8. Farmaceutische samenstelling volgens een van de conclusies 1-7, waarin de excipienten die worden gebruikt zijn gekozen uit de groep die bestaat uit microkristallijn cellulose, hydroxypropylcellulose, magnesiumstearaat, of stearinezuur. 30
9. Farmaceutische samenstelling volgens een van de conclusies 1-8, waarin de samenstelling is geformuleerd als een tablet, een suiker bekleedde capsule, pastille, vloeistof of drinkbare suspensie of zalf.
10. Farmaceutische samenstelling volgens een van de conclusies 1-9, voor gebruik in de preventie en behandeling van gingivitis of parodontitis in mensen of dieren.
11. Farmaceutische samenstelling volgens conclusie 10, waarin de menselijke of 5 dierlijke patiënten een totale dagelijkse dosis krijgen toegediend van 10-200 mg/kg lichaamsgewicht van de samenstelling, bij voorkeur 25-150 mg/kg lichaamsgewicht, meest bij voorkeur 75-125 mg/kg.
12. Farmaceutische samenstelling volgens conclusie 10 of 11, waarin de farmaceutische 10 samenstelling eenmaal of tweemaal per dag wordt toegediend.
13. Farmaceutische samenstelling volgens een van de conclusies 10-12, waarin een eenheidsdosering voor mensen omvat 400 mg tot 2000 mg, bij voorkeur 500 tot 1250 mg en meest bij voorkeur circa 1000 mg. 15
14. Farmaceutische samenstelling volgens een van de conclusies 10-12, waarin een eenheidsdosering voor dieren omvat 200 tot 1000 mg, bij voorkeur 300 tot 600 mg, meest bij voorkeur circa 550 mg.
15. Farmaceutische samenstelling volgens een van de conclusies 10-14, waarin de samenstelling wordt toegediend aan mensen die een geschiedenis hebben van het lijden aan gingivitis of parodontitis.
16. Werkwijze voor het vervaardigen van een farmaceutische samenstelling volgens een 25 van de conclusies 1-9.
17. Kit omvattende een farmaceutische samenstelling volgens een van de conclusies 1- 9.
18. Kit volgens conclusie 17, waarin de kit is een doordrukverpakking of een houder.
NL2005194A 2010-08-05 2010-08-05 Pharmaceutical composition for use in the prevention and treatment of gingivitis and parodontitis. NL2005194C2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
NL2005194A NL2005194C2 (en) 2010-08-05 2010-08-05 Pharmaceutical composition for use in the prevention and treatment of gingivitis and parodontitis.
BE2011/0484A BE1020183A3 (nl) 2010-08-05 2011-08-05 Farmaceutische samenstelling voor gebruik bij de behandeling en preventie van gingivitis en parodontitis.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NL2005194A NL2005194C2 (en) 2010-08-05 2010-08-05 Pharmaceutical composition for use in the prevention and treatment of gingivitis and parodontitis.
NL2005194 2010-08-05

Publications (1)

Publication Number Publication Date
NL2005194C2 true NL2005194C2 (en) 2012-02-07

Family

ID=43088284

Family Applications (1)

Application Number Title Priority Date Filing Date
NL2005194A NL2005194C2 (en) 2010-08-05 2010-08-05 Pharmaceutical composition for use in the prevention and treatment of gingivitis and parodontitis.

Country Status (2)

Country Link
BE (1) BE1020183A3 (nl)
NL (1) NL2005194C2 (nl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014161872A1 (en) * 2013-04-05 2014-10-09 Nestec S.A. Compositions for use in stimulating bone growth

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1072254A1 (en) * 1998-04-24 2001-01-31 Sunstar Inc. Food compositions, compositions for oral cavity and medicinal compositions for preventing or treating periodontosis and method for preventing or treating periodontosis
WO2004010962A1 (en) * 2002-07-31 2004-02-05 Bon-Gil Koo Liquid composition for protecting oral cavities and teeth of pet animals and use thereof in plaything for pet animals
WO2004012522A1 (en) * 2002-07-26 2004-02-12 Dsm Ip Assets B.V. Compositions comprising lactoferrin
CN1615744A (zh) * 2004-12-08 2005-05-18 肖新房 一种延缓衰老的保健食品
WO2006069241A2 (en) * 2004-12-22 2006-06-29 Hill's Pet Nutrition, Inc. Methods for promoting oral health in animals
WO2006069662A1 (en) * 2004-12-31 2006-07-06 Dsm Ip Assets B.V. Pet food
US20070129316A1 (en) * 2001-12-18 2007-06-07 Daicho Kikaku Incorporated Company Muscle-strengthening drugs and anti-inflammatory drugs
WO2008025468A1 (en) * 2006-08-31 2008-03-06 Dsm Ip Assets B.V. Oral care effervescent composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002029953A (ja) * 2000-07-19 2002-01-29 Sunstar Inc 歯周病の予防または治療用の食品組成物、口腔用組成物
DE10257478A1 (de) * 2002-12-09 2004-07-08 Dahlhaus, Ulrich, Dr. Parodontitis- und Osteoporoseprävention
JP2005112852A (ja) * 2003-09-19 2005-04-28 Sunstar Inc 歯肉の炎症及び歯根膜喪失を抑制するための内服組成物

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1072254A1 (en) * 1998-04-24 2001-01-31 Sunstar Inc. Food compositions, compositions for oral cavity and medicinal compositions for preventing or treating periodontosis and method for preventing or treating periodontosis
US20070129316A1 (en) * 2001-12-18 2007-06-07 Daicho Kikaku Incorporated Company Muscle-strengthening drugs and anti-inflammatory drugs
WO2004012522A1 (en) * 2002-07-26 2004-02-12 Dsm Ip Assets B.V. Compositions comprising lactoferrin
WO2004010962A1 (en) * 2002-07-31 2004-02-05 Bon-Gil Koo Liquid composition for protecting oral cavities and teeth of pet animals and use thereof in plaything for pet animals
CN1615744A (zh) * 2004-12-08 2005-05-18 肖新房 一种延缓衰老的保健食品
WO2006069241A2 (en) * 2004-12-22 2006-06-29 Hill's Pet Nutrition, Inc. Methods for promoting oral health in animals
WO2006069662A1 (en) * 2004-12-31 2006-07-06 Dsm Ip Assets B.V. Pet food
WO2008025468A1 (en) * 2006-08-31 2008-03-06 Dsm Ip Assets B.V. Oral care effervescent composition

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAI F ET AL: "Antioxidant synergism of green tea polyphenols with alpha-tocopherol and l-ascorbic acid in SDS micelles", BIOCHIMIE, MASSON, PARIS, FR, vol. 90, no. 10, 1 October 2008 (2008-10-01), pages 1499 - 1505, XP025405376, ISSN: 0300-9084, [retrieved on 20080523], DOI: DOI:10.1016/J.BIOCHI.2008.05.007 *
DATABASE WPI Week 200566, Derwent World Patents Index; AN 2005-640122 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014161872A1 (en) * 2013-04-05 2014-10-09 Nestec S.A. Compositions for use in stimulating bone growth
JP2016520544A (ja) * 2013-04-05 2016-07-14 ネステク ソシエテ アノニム 骨成長の刺激における使用のための組成物
AU2014247122B2 (en) * 2013-04-05 2018-12-06 Société des Produits Nestlé S.A. Compositions for use in stimulating bone growth
JP2020058351A (ja) * 2013-04-05 2020-04-16 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 骨成長の刺激における使用のための組成物
US10675290B2 (en) 2013-04-05 2020-06-09 Societe Des Produits Nestle S.A. Compositions for use in stimulating bone growth
US11166965B2 (en) 2013-04-05 2021-11-09 Societe Des Produits Nestle S.A. Compositions for use in stimulating bone growth
JP2022031660A (ja) * 2013-04-05 2022-02-22 ソシエテ・デ・プロデュイ・ネスレ・エス・アー 骨成長の刺激における使用のための組成物

Also Published As

Publication number Publication date
BE1020183A3 (nl) 2013-06-04

Similar Documents

Publication Publication Date Title
AU2016204931B2 (en) Method of producing physiological and therapeutic levels of nitric oxide through an oral delivery system
KR20080021024A (ko) 지연성 화학요법-유발 메스꺼움 및 구토의 드로나비놀 치료
WO2016043524A1 (ko) 망고스틴 추출물 또는 알파, 감마 망고스틴을 유효성분으로 포함하는 치주질환 예방 또는 개선용 조성물
MX2007015838A (es) Dronabinol para el tratamiento de migranas.
US20190091274A1 (en) Maca compositions and methods of use
US20080181937A1 (en) Dosage regimen and medicament for guarding memory and brain health and for preventing or reducing risk of onset of dementia by administration of specific vitamins and supplements (memoguard)
NL2005194C2 (en) Pharmaceutical composition for use in the prevention and treatment of gingivitis and parodontitis.
US6159986A (en) Compounds and therapy for resisting memory loss in humans
JP2007112795A (ja) アントラキノン系薬剤含有下剤医薬組成物
US10391139B2 (en) Blood pressure reduction with dietary supplements
CA2528365A1 (en) Asenapine for the treatment of schizophrenia in a patient with overweight or predisposition for overweight
CN101450114A (zh) 一种具有抗氧化、延缓衰老功能的药物组合物及其制备方法
CN113018294A (zh) 一种香叶木素用途
US20140271908A1 (en) Dietary supplements and methods for preventing and treating migraines
US11857594B2 (en) Curcumin compositions and methods of use as an NK3 antagonist
CN101449818A (zh) 一种具有延缓女性衰老功能的药物组合物及其制备方法
US20220249442A1 (en) Synergistic combination therapy for treating als
RU2414231C1 (ru) Антиоксидантное средство
CA3076180C (en) Benzoic acid or a salt and derivative thereof for use in preventing or treating depression
JP4896531B2 (ja) 血中ＣｏＱ１０量を増加させる医薬組成物
CA3207330A1 (en) Supplement for arthritis and psoriasis
US20200197294A1 (en) Novel cannabis lines and extracts for skin rejuvenation and skin protection
CN118160923A (zh) 一种抗氧化组合物及其应用
Goodland et al. Cannabidiol improves learning and memory deficits and alleviates anxiety in 12-month-old SAMP8 Mice
WO2023158641A1 (en) Synergistic combination therapy for treating als

Legal Events

Date Code Title Description
MM Lapsed because of non-payment of the annual fee

Effective date: 20150901